Renova assembles the team for RT-100's next trial
Summary
Renova Therapeutics has brought together the clinical, regulatory, and manufacturing team that will take RT-100, its gene therapy for heart failure, into its next clinical study.
PASADENA, California — Renova Therapeutics has brought together the clinical, regulatory, and manufacturing team that will take RT-100, its gene therapy for heart failure, into its next clinical study.
RT-100 was evaluated in a 56-patient randomized, placebo-controlled trial published in JAMA Cardiology in 2016. The therapy has held FDA Fast Track designation since then. What the program has needed is the group of people who can carry it from a published result into a larger trial.
Rickey Reinhardt, MD, PhD leads clinical development strategy. He spent 30 years in drug development across gene therapy and cardiovascular disease, including as Chief Medical Officer of XyloCor Therapeutics, which ran the closest clinical analog to RT-100.
Marc Semigran, MD advises on endpoints and safety. He led the Heart Failure and Cardiac Transplant Program at Massachusetts General Hospital and served as Chief Medical Officer of MyoKardia through the mavacamten clinical development program.
Julie Hagan, MS leads regulatory affairs, with more than 20 years of regulatory experience working across gene therapy, cell therapy, and rare disease programs. Julie has been involved in clinical development programs at companies such as Human Genome Sciences (HGS), Orchard Therapeutics, and REGENXBIO.
Raj Poudel, PhD leads CMC strategy. He is Head of CMC at Mammoth Biosciences and has worked on the manufacturing behind Breyanzi and Abecma.
Stephen Kaminsky, PhD advises on manufacturing and technology transfer. He is Associate Director of Weill Cornell's Belfer Gene Therapy Core Facility, which produced the clinical material for RT-100's original trial.
“The data from the first trial have been sitting there since 2016,” said Alan Horsager, PhD, President and CEO. “What this program needed wasn't another idea. It needed people who have run this kind of study before and know where it goes wrong. That's what we have now.”
“I have worked on AC6 gene therapy since 1992 and submitted the IND for its first clinical trial, which I subsequently directed,” said H. Kirk Hammond, MD, founder of Renova and chair of its Scientific Advisory Board. “What gives me confidence today is the experienced team guiding the program. They understand the challenges of clinical development and FDA approval and bring the scientific rigor and judgment needed to move this work forward.”
Renova is preparing a Phase 2b trial of RT-100 in patients with non-ischemic heart failure with reduced ejection fraction.
Full biographies are on the team page.
RT-100 is an investigational therapy. It has not been approved by the FDA or any other regulatory agency and is available only within clinical trials.

